Plain-English translation of NCT03736863 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing different combinations of medications—including Apatinib paired with either Camrelizumab or Adebrelimab, and other drug pairs—for people with advanced esophageal squamous cell carcinoma that has progressed or stopped responding to initial treatment. Researchers want to find which medication combination works best and is safest when standard first-line treatments no longer help.
When esophageal cancer progresses after chemotherapy or immunotherapy, doctors don't yet have a clear standard approach for what to try next. This trial exists to explore whether these new medication combinations can help patients whose cancer has become resistant to earlier treatments.
You will receive intravenous infusions of the medication combination assigned to your group every three weeks. Depending on which arm you are placed in, you may receive Apatinib plus Camrelizumab, Apatinib plus Adebrelimab, or Adebrelimab plus another medication. You will have regular blood tests and imaging scans to monitor how your cancer responds and to watch for any side effects. The study also requires providing tissue samples for research.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital of Zhengzhou University
Enrollment target
~147 participants
Started
December 2019
Primary completion
June 2021
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Feng Wang
The First Affiliated Hospital of Zhengzhou University